2024-513597-22-00招募中4 期
Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: a pragmatic clinical trial [PREMI study]
Institut Universitari D Investigacio En Atencion Primaria Jordi Gol12 个研究点 分布在 1 个国家目标入组 460 人开始时间: 2024年10月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 460
- 试验地点
- 12
- 主要终点
- Clinical effectiveness: change in the mean number of monthly migraine days (MMD) at 12 weeks of treatment from baseline.
研究概览
简要总结
To evaluate the effectiveness of the most frequently used drugs in the first line in primary care for the preventive treatment of migraine according to the reduction in monthly migraine days, comparing amitriptyline, flunarizine and topiramate with propranolol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Study Arms
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Adults (≥18) candidates for preventive treatment for migraine; those with a frequency of ≥4 monthly migraine days, and who agree to participate in the clinical trial.
排除标准
- •People diagnosed with migraine who are not candidates for preventive migraine treatment
- •People diagnosed with chronic migraine (>15 days of headache per month, of which 8 are monthly migraine days)
- •Not having a smartphone
- •Simultaneous participation in another clinical trial
- •Pregnancy or expected pregnancy during the next 3 months
- •People with migraine who already receive preventive treatment.
- •People on chronic treatment with opioids or other analgesics or NSAIDs that are not used for the symptomatic treatment of migraine, for example, osteoarthritis.
- •People who, in the opinion of the clinician, have an absolute contraindication to one of the study drugs or who cannot perform the trial procedures: - Hypersensitivity to any of the study drugs - Heart block or severe bradycardia - Concomitant treatment with verapamil or diltiazem - Active cardiovascular pathology (recent heart attack, angina, Raynaud's phenomenon) - Major depression or active treatment with antidepressants (including monoamine oxidase inhibitors and St. John's wort) - Other psychiatric illnesses or active treatment with antipsychotics or lithium - Severe liver disease or kidney failure - Parkinson's disease or other extrapyramidal disorders - Epilepsy (diagnosis and/or active treatment) - Any other contraindication that, in the opinion of the clinician, prevents participation in the clinical trial
结局指标
主要结局
Clinical effectiveness: change in the mean number of monthly migraine days (MMD) at 12 weeks of treatment from baseline.
Clinical effectiveness: change in the mean number of monthly migraine days (MMD) at 12 weeks of treatment from baseline.
次要结局
- Proportion of patients responding at 12 weeks from start of treatment; <25% change in mean number of MMD: non-responders, 25-49%: partial responders, 50-75%: responders, >75%: excellent responders.
- Change in mean number of MMDs at 4 and 8 weeks from baseline.
- Reduction in the mean number of moderate-severe MMD at 4, 8 and 12 weeks from the start of treatment.
- Proportion of patients with associated symptoms at 12 weeks from the start of treatment; photophobia, phonophobia, nausea.
- Proportion of adherent and non-adherent patients (according to taking [yes/no] of the study treatment with the prescribed dosage) at 12 weeks from the start of treatment.
- Change in the mean number of drugs used for symptomatic treatment at 4, 8 and 12 weeks from baseline.
- Reconsultations: Type of consultation (PCC, PC emergency, hospital, hospital emergency). Number of consultations after 12 weeks from the start. Number of medical tests performed relacionadas con la migraña.
- Patients' Global Impression of Change (PGIC) scale at 12 weeks.
- Change in EQ-5D-5L questionnaire at 12 weeks from baseline.
- Change in HIT-6 questionnaire at 12 weeks from baseline.
- Change in the number of ILT days, absenteeism, presenteeism at 12 weeks from the start of treatment.
- Adherence to treatment 6 months after the start of the trial.
- Switching or discontinuation of drug for preventive treatment after 6 months from the start of the trial.
研究者
Maria Giner-Soriano
Scientific
Institut Universitari D Investigacio En Atencion Primaria Jordi Gol
研究点 (12)
Loading locations...
相似试验
已完成
4 期
Efficacy and safety of the medications of first line treatment (artesunate+amodiaquine) and second line treatment (artemether+lumefantrine) for the treatment of uncomplicated Plasmodium falciparum in Malabo, Bata and Ebibey, Equatorial GuineeMalariaACTRN12617000456358Ministry of Public Health of Equatorial Guinea528
已完成
1 期
Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XRHealthy VolunteersNCT02185066HK inno.N Corporation42
已完成
不适用
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).Metastatic Renal Cell CarcinomaNCT05858749Pfizer494
已完成
不适用
Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EuropeImplantable Defibrillator UserMyocardial InfarctionDilated CardiomyopathyCoronary Artery DiseaseNCT02064192University Medical Center Goettingen2,285
尚未招募
1 期
Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. AureusStaphylococcal InfectionsDiabetic FootNCT02664740Centre Hospitalier Universitaire de Nīmes60